Mesoblast Limited Provides Corporate Strategy for Product Development to Treat Neurologic Conditions
Published: Jun 08, 2012
In an update on Mesoblast’s strategic alliance with Teva Pharmaceutical Industries Ltd in the fields of neurologic and cardiovascular diseases, Chief Executive Professor Silviu Itescu discussed plans to commercially develop Mesoblast’s proprietary allogeneic, or off-the-shelf, adult dental pulp stem cells (DPSC) for stroke, spinal cord injury, Parkinson’s and Huntington’s diseases.
Mesoblast has exclusive worldwide commercial rights to granted composition of matter patents covering DPSC, which are STRO-1 positive Mesenchymal Precursor Cells (MPCs) of neural crest origin. These cells produce significantly greater levels of neurotrophic factors and are significantly more effective than other adult stem cell types for neural differentiation and repair of various neural cells and tissues.
Recent published reports have shown that DPSC may be effective for protection and repair of neural tissue after spinal cord injury and stroke.
Professor Itescu additionally updated attendees on outcomes from recent meetings with regulatory authorities in the United States and Europe in regards to the upcoming commencement of the congestive heart failure Phase 3 trial. He said that the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) were aligned on the clinical trial design and the primary and secondary endpoints.
A copy of the presentation to the conference is attached.
Mesoblast Limited (ASX:MSB) is a world leader in commercialising biologic products for the broad field of regenerative medicine. Mesoblast has the worldwide exclusive rights for a series of patents and technologies developed over more than 10 years relating to the identification, extraction, culture and uses of adult Mesenchymal Precursor Cells (MPCs).
For further information, please contact:
T: + 61 (0) 3 9639 6036
For media queries, please contact:
Melanie Toyne Sewell/Gemma Howe
T: + 44 20 7866 7860